August 2012 Editor's Picks: Products from Getinge and MG America - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

August 2012 Editor's Picks: Products from Getinge and MG America

Equipment and Processing Report

August 2012 Editor's Picks: Products from Getinge and MG America
Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Getinge

Rigid-wall isolators improve productivity of sterility testing.
Sterility testing in an isolator helps avoid false-positive or false-negative results, and Getinge-La Calhène’s Isotest stainless-steel, rigid-wall isolators are designed to improve the workflow for sterility testing of injectables. The Isotest is equipped with one or two workstations in the same chamber, an attached fast decontamination chamber, and Getinge’s DPTE transfer system to evacuate the test canister and solid/liquid waste. The Isotest integrated bio-decontamination system is self-contained. Isotest can bio-decontaminate either the working chamber or the fast-decontamination chamber using the Isotest PLC control-system touch screen. Hydrogen peroxide is delivered from a canister that includes an RFID chip, which allows the PLC to monitor the volume and remaining shelf life, thus providing full traceability.


MG America
Versatile capsule filler with multiple dosing units is designed for small runs.

MG America’s FlexaLAB capsule filler, which can produce up to 3000 capsules per hour, is designed for research and development, clinical trials, and small-batch production. The FlexaLAB can function with either continuous or intermittent motion. Installing multiple dosing units allows the FlexaLAB to manufacture capsules with combinations of products. The machine can fill powders, pellets, microtablets, tablets, liquids, and certain low-dosage powder inhalants and can perform capsule-into-capsule functions. The machine includes a touch-screen panel and PLC for machine-functions control. Machine speed can be adjusted from the monitor.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Equipment and Processing Report,
Click here